Orexigen™ Therapeutics, Inc. reported in October 2006, that Empatic™, formerly known as Excalia™, which is a combination of two centrally-acting medications intended to provide and sustain clinically important weight loss, demonstrated significant weight loss in a six month, double-blind, phase IIa clinical study. Patients completing the blinded 24-week phase averaged a 9.2% loss from their baseline while using Empatic compared to an average of 0.4% weight loss from baseline for patients using placebo. Those patients continuing through an additional 24 weeks had an average weight loss of 12% from baseline by 48 weeks. These top line phase IIa data for Empatic were presented at the annual meeting of the North American Association for the Study of Obesity (NAASO) in Boston.
Empatic is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, plus zonisamide, an approved anticonvulsant medication. Orexigen's preclinical research suggests that combining these two central nervous system drugs acts on a complex of neurons in the hypothalamus, the area of the brain contributing to the regulation of appetite, energy output and maintaining body weight.
Information in this post came from an Orexigen Press release. You can view the entire release at http://ir.orexigen.com/releasedetail.cfm?ReleaseID=224841.
Empatic is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, plus zonisamide, an approved anticonvulsant medication. Orexigen's preclinical research suggests that combining these two central nervous system drugs acts on a complex of neurons in the hypothalamus, the area of the brain contributing to the regulation of appetite, energy output and maintaining body weight.
Information in this post came from an Orexigen Press release. You can view the entire release at http://ir.orexigen.com/releasedetail.cfm?ReleaseID=224841.
posted by Ken MacKenzie @ 10:05 AM
0 comments
